Personalized chemotherapy before surgery for borderline pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of pancreatic cancer that is borderline resectable (doctors think it may be removable with surgery, but it is close to important blood vessels).
- You have not had chemotherapy or radiation for this cancer before (except for one round of a standard chemo given while waiting for test results).
- A tissue sample (biopsy) from your tumor must be available for genetic testing.
- You are 18 to 80 years old (if you are 76-80, you must pass a special health check).
- Your cancer has not spread to distant organs or faraway lymph nodes.
- Your liver, kidney, and blood counts are within acceptable ranges, and you are fit enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before surgery to shrink the tumor in people with a specific type of pancreatic cancer. The goal is to make surgery more effective and improve outcomes.
This trial tests a combination of three chemotherapy drugs given before surgery for pancreatic cancer that is removable or borderline removable. The goal is to shrink the tumor to make surgery more successful.
This trial tests whether choosing chemotherapy based on a SMAD4 gene change in your tumor works better than the usual approach for pancreatic cancer that can be surgically removed. If you have the gene change, you may get a different chemotherapy combination to improve outcomes.
This trial tests a combination of chemotherapy drugs (mFOLFIRINOX) given before surgery to people with pancreatic cancer that may be removable. The goal is to see if this approach works well and to prepare for a larger study.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.